Next Science Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
Metrics to compare | NXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNXSPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.5x | −4.0x | −0.5x | |
PEG Ratio | −0.05 | −0.29 | 0.00 | |
Price/Book | 7.7x | 4.1x | 2.6x | |
Price / LTM Sales | 1.2x | 6.1x | 3.2x | |
Upside (Analyst Target) | 87.7% | 68.1% | 44.3% | |
Fair Value Upside | Unlock | 3.6% | 6.6% | Unlock |